KRAS and breast carcinoma: Although KRAS mutations are not commonly found in breast cancer, the pathway seems to be hyperactive due to mutation in NF1, epigenetic silencing of DUSP4 or other alternatives that lead to non-canonical MAPK activation [6, 7].